Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.41 |
| ▸ | TYMP | P19971 | 3/20 | 0.40 |
| ▸ | TK2 | O00142 | 3/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112758 | 0.90 | TYMP (0.40) | TYMPTSHRLMNAMAPTPMP22 | |
| SCHEMBL2114242 | 0.89 | PYGM (0.45) | PYGMP2RY6TYMPTK2P2RY2 | |
| SCHEMBL2115511 | 0.89 | PYGM (0.43) | PYGMP2RY6P2RY14TK2P2RY2 | |
| SCHEMBL5086844 | 0.85 | TK1 (0.47) | TK1 | |
| SCHEMBL442715 | 0.84 | P2RY14 (0.48) | P2RY6P2RY14P2RY2 | |
| SCHEMBL9294173 | 0.83 | TYMP (0.37) | TYMPTK2TK1 | |
| SCHEMBL8197884 | 0.80 | TYMP (0.62) | PYGMP2RY6P2RY14TYMPP2RY2 | |
| SCHEMBL7264129 | 0.80 | TYMP (0.62) | PYGMP2RY6P2RY14TYMPP2RY2 | |
| SCHEMBL5134596 | 0.80 | TK1 (0.40) | TYMPTK2TK1 | |
| SCHEMBL8592454 | 0.79 | RNASE1 (0.44) | TYMPTK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158770-B2 | Content dependent inhibitors of cytidine deaminases and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| EP-1042345-B1 | COMPOUNDS FOR MASS SPECTROMETRY COMPRISING NUCLEIC ACID BASES AND ARYL ETHER MASS MARKERS | XZILLION GMBH & CO KG (DE) | 2003-04-16 | — | — | EP | disclosed |
| EP-1095053-B1 | ARYLSULFONE LINKERS FOR MASS SPECTROMETRIC ANALYSIS | XZILLION GMBH & CO KG (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-6287780-B1 | Compounds for mass spectrometry comprising nucleic acid bases and aryl ether mass markers | BRAX GROUP LIMITED (GB) | 2001-09-11 | — | — | US | disclosed |
| EP-1095053-A1 | ARYLSULFONE LINKERS FOR MASS SPECTROMETRIC ANALYSIS | Brax Group Limited (GB) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002895-A1 | ARYLSULFONE LINKERS FOR MASS SPECTROMETRIC ANALYSIS | BRAX GROUP LIMITED (GB) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | PYGM 1390/4885P2RY6 3383/4885P2RY14 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.